This article dissects Montagu Private Equity's ambitious rollup of three orthopedic device companies, comparing it to their proven Nemera playbook, to reveal strategic synergies, growth prospects, and risks that could shape the future of medical innovation and investor returns.
Let's jump in.
Montagu Private Equity, leveraging its established carve-out and rollup expertise from deals like Nemera's drug delivery platform, is now applying a similar playbook to the orthopedic device sector. Historically, Montagu has excelled in healthcare investments, completing over 30 carve-outs since 2002, including Nemera (carved from Rexam in 2014) and Resolve Surgical Technologies (spun from RTI Surgical in 2021 as Evergen). These moves often target undervalued assets in resilient markets, enhancing them through operational efficiencies, M&A, and innovation. In Nemera's case, this involved rolling up three acquisitions (Insight, Copernicus, Milfra) to expand from Europe-focused contract manufacturing to a global, integrated drug delivery leader, driving 50% sales growth.
Fast forward to 2025, Montagu announced the acquisition of Tyber Medical for an undisclosed sum, merging it with its exis...
